Investment Thesis
Replimune is a pre-revenue biotech company with no commercialized products, posting $246.6M in operating losses and burning $228.4M in free cash flow annually. Despite a solid cash position of $123M and conservative leverage (0.23x D/E), the burn rate implies only 6-7 months of runway at current spending levels, necessitating immediate capital raises or dramatic operational changes to avoid liquidity crisis.
Strengths
- Strong cash position of $123.0M provides near-term operational runway
- Conservative leverage with 0.23x debt-to-equity ratio and low absolute debt of $47.6M
- Excellent liquidity ratios (5.60x current/quick ratio) indicate ability to meet short-term obligations
- Significant insider activity (16 Form 4 filings in 90 days) suggests management confidence in pipeline
Risks
- Pre-revenue company with zero sales indicates no validated commercial products
- Massive annual cash burn of $228.4M (free cash flow) against only $123M cash on hand
- Operating losses of $246.6M with negative ROE (-114.3%) and ROA (-72.2%) demonstrate unprofitable operations
- Only 6-7 months of cash runway at current burn rate; requires external financing or operational pivot
- High clinical/regulatory execution risk typical of early-stage biotech with no approved products
Key Metrics to Watch
- Cash burn rate and remaining runway (critical for survival)
- Clinical trial progress and FDA regulatory milestones for pipeline programs
- Cash position and capital raise announcements or dilution
- Operating expense trends and whether burn rate can be reduced
Financial Metrics
Revenue
0.0
Net Income
-240.7M
EPS (Diluted)
$-2.62
Free Cash Flow
-228.4M
Total Assets
333.6M
Cash
123.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-114.3%
ROA
-72.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
5.60x
Quick Ratio
5.60x
Debt/Equity
0.23x
Debt/Assets
36.9%
Interest Coverage
-55.67x
Long-term Debt
47.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-08T21:20:22.024033 |
Data as of: 2025-12-31 |
Powered by Claude AI